| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| Other Sizes |
| Targets |
This compound does not have a specific biological target; it is a fluorescent probe that non‑covalently binds to proteins (e.g., streptavidin, antibodies) and DNA through conjugation. Its fluorescence can be detected by fluorescence microscopy, flow cytometry, or fluorescence plate readers.
|
|---|---|
| ln Vitro |
6‑TAMRA free acid is a fluorophore widely used as a fluorescent label. Its in vitro activity is defined by its spectral properties (excitation/emission maxima), quantum yield, and photostability. It is used to label antibodies, peptides, oligonucleotides, and other biomolecules to enable their detection and visualization in biological experiments.
|
| ln Vivo |
This compound does not have an independent in vivo activity; it is used as a label for biomolecules that are then administered in vivo. TAMRA‑labeled molecules can be used for in vivo imaging applications. Biodistribution and tumor targeting can be assessed by fluorescence imaging of live animals after administration of TAMRA‑labeled antibodies, peptides, or nanoparticles.
|
| Enzyme Assay |
General cell‑free protocol for labeling antibodies with 6‑TAMRA free acid: Purified antibody (1‑2 mg/mL) is dialyzed against 0.1 M sodium bicarbonate buffer (pH 8.3). 6‑TAMRA free acid is activated with N‑hydroxysuccinimide (NHS) and DCC to form the NHS ester derivative (6‑TAMRA‑SE). The NHS ester is dissolved in DMSO at 10 mg/mL. Varying amounts of the NHS ester (5‑50 molar equivalents) are added to the antibody solution and incubated for 1‑2 hours at room temperature or overnight at 4degC. Unreacted dye is removed by size exclusion chromatography (Sephadex G‑25) or dialysis. The degree of labeling (DOL) is calculated by measuring absorbance at 280 nm (protein) and 546 nm (TAMRA) and is typically adjusted to 2‑5 dyes per antibody.
|
| Cell Assay |
General cellular protocol for 6‑TAMRA free acid: Cells are grown on coverslips or in 96‑well plates and fixed with 4% paraformaldehyde. Permeabilization (if needed) is performed with 0.1% Triton X‑100. Cells are blocked with 3% BSA or normal serum. Cells are then incubated with a TAMRA‑labeled primary antibody (e.g., anti‑tubulin‑TAMRA) or TAMRA‑labeled streptavidin (for biotinylated probes) at 1‑10 ug/mL for 1 hour at room temperature or overnight at 4degC. After washing, the cells are counterstained with DAPI (nuclear stain) and imaged by fluorescence microscopy using a rhodamine/TAMRA filter set (excitation 540‑560 nm, emission 570‑620 nm). For flow cytometry, cells are stained with TAMRA‑labeled antibodies, washed, and analyzed on a flow cytometer equipped with a 561 nm (or 488 nm) laser and appropriate emission filters.
|
| Animal Protocol |
A general animal protocol for 6‑TAMRA free acid‑labeled probes: For in vivo imaging, TAMRA‑labeled probes (e.g., TAMRA‑labeled antibodies, nanoparticles, or peptides) are administered to mice via intravenous (IV) injection at doses of 0.1‑5 mg/kg. Mice are anesthetized with isoflurane and imaged at various time points (1, 4, 8, 24, 48 hours) using a fluorescence imaging system (e.g., IVIS Spectrum) with excitation filters at 535 nm and emission filters at 580 nm (or as recommended for TAMRA). At the end of the study, mice are euthanized, and organs (tumor, liver, spleen, kidney, heart, lung) are harvested for ex vivo fluorescence imaging to assess probe biodistribution and tumor targeting.
|
| ADME/Pharmacokinetics |
General PK protocol for 6‑TAMRA free acid is not applicable. For TAMRA‑labeled antibodies or nanoparticles, a standard PK protocol would involve IV administration to mice, blood collection at multiple time points, and quantification of TAMRA fluorescence in plasma using a fluorescence plate reader. PK parameters (Cmax, Tmax, AUC, t½) are calculated.
|
| Toxicity/Toxicokinetics |
General toxicity of 6‑TAMRA free acid itself is not typically assessed because it is a small molecule used in low concentrations for labeling. TAMRA is considered non‑toxic and has good biocompatibility at the concentrations used for labeling. For TAMRA‑labeled biomolecules, a single‑dose toxicity study in mice can be performed: the labeled molecule is administered IV at doses of 1, 5, and 25 mg/kg, and animals are observed for 14 days for clinical signs and body weight changes.
|
| Additional Infomation |
6‑TAMRA free acid has the molecular formula C2₅H22N2O₅ and a molecular weight of 430.45 g/mol. It is also known as 6‑carboxytetramethylrhodamine. The compound is a bright, orange‑red fluorescent dye with a high quantum yield and excellent photostability. TAMRA is one of the most commonly used fluorophores in biological research, along with fluorescein (FITC), Cy3, and Cy5. The “free acid” form contains a carboxylic acid group that can be activated to an NHS ester for conjugation to amines on proteins and other biomolecules. For research use only; not for therapeutic or diagnostic use.
|
| Molecular Formula |
C25H22N2O5
|
|---|---|
| Molecular Weight |
430.45
|
| Exact Mass |
430.152
|
| CAS # |
150322-06-8
|
| PubChem CID |
9802745
|
| Appearance |
Solid powder
|
| LogP |
3.727
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
32
|
| Complexity |
723
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CN(C)C1=CC2OC3C(C4(C5C(=CC=C(C(O)=O)C=5)C(=O)O4)C=2C=C1)=CC=C(N(C)C)C=3
|
| InChi Key |
AIOHJULCHGRPMK-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C25H22N2O5/c1-26(2)15-6-9-18-21(12-15)31-22-13-16(27(3)4)7-10-19(22)25(18)20-11-14(23(28)29)5-8-17(20)24(30)32-25/h5-13H,1-4H3,(H,28,29)
|
| Chemical Name |
3',6'-bis(dimethylamino)-1-oxospiro[2-benzofuran-3,9'-xanthene]-5-carboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3232 mL | 11.6158 mL | 23.2315 mL | |
| 5 mM | 0.4646 mL | 2.3232 mL | 4.6463 mL | |
| 10 mM | 0.2323 mL | 1.1616 mL | 2.3232 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
